https://www.bioworld.com/rss en-us Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions. http://www.bioworld.com/articles/732621 Fri, 10 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732621-microbial-ecology-reshapes-cancer-care-diagnostics-and-therapies Illustration of bacteria, microorganisms in the gastrointestinal system U&S Bio Co. Ltd. has divulged H+/K+-ATPase inhibitors with improved stability found to be potentially useful for the treatment of gastrointestinal disorders, cancer, Helicobacter pylori infection, sialorrhea, asthma and airways obstruction, among others. Helicobacter pylori infection, sialorrhea, asthma and airways obstruction, among others.]]> http://www.bioworld.com/articles/732511 Thu, 09 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732511-u-and-s-bio-identifies-new-h-k-atpase-inhibitors While the emergence of immune checkpoint inhibitor (ICI) therapy in recent years has significantly improved cancer outcomes, some patients have been unable to experience the full therapeutic benefits of ICIs due to significant gastrointestinal inflammation linked to treatment. Seres Therapeutics Inc. is looking to change that with its live biotherapeutic candidate, SER-155, offering impressive findings from phase I data in ICI-related enterocolitis, or irEC. http://www.bioworld.com/articles/732435 Wed, 08 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732435-seres-ser-155-takes-on-immune-checkpoint-inhibitor-related-enterocolitis Illustration of intestinal track Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions. http://www.bioworld.com/articles/732480 Wed, 08 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732480-microbial-ecology-reshapes-cancer-care-diagnostics-and-therapies Illustration of bacteria, microorganisms in the gastrointestinal system Tvardi Therapeutics Inc. rebounded from a phase II blowup last fall in idiopathic pulmonary fibrosis (IPF) with oral STAT3 inhibitor TTI-101 by showing that a next-gen phosphate prodrug dubbed TTI-109 kept its potency in phase I without gastrointestinal (GI) troubles. http://www.bioworld.com/articles/732418 Tue, 07 Jul 2026 12:00:00 -0400 https://www.bioworld.com/articles/732418-with-tardy-tvardi-phase-i-win-skin-in-stat3-game-plus-gi Stock chart, upward arrow Ribocure Pharmaceuticals AB, a subsidiary of Suzhou Ribo Life Science Co. Ltd., and Madrigal Pharmaceuticals Inc. have achieved the first drug candidate nomination within their siRNA partnership. http://www.bioworld.com/articles/732357 Thu, 02 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732357-ribocure-and-madrigal-nominate-sirna-drug-candidate-for-mash Illustration of RNA strands being delivered by nanoparticles Trex Bio Inc. has disclosed that its development candidate TRB-071, currently in IND-enabling studies, is a CD30 agonist antibody. The approach could have therapeutic potential in inflammatory bowel disease and other autoimmune and inflammatory diseases. http://www.bioworld.com/articles/732331 Wed, 01 Jul 2026 09:00:00 -0400 https://www.bioworld.com/articles/732331-trex-bio-discloses-trb-071-as-cd30-agonist-antibody Illustration of intestines with inflammation Wall Street breathed easier, and shares of Abivax SA found relief as further phase III data from the Abtect maintenance trial were disclosed with obefazimod in ulcerative colitis (UC). http://www.bioworld.com/articles/732245 Tue, 30 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732245-relaxed-on-abivax-uc-phase-iii-cancer-answer-quells-fretting The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of antidepressant-naive patients presented at the 2026 World Congress of Neuropsychopharmacology (CINP), scientists from National Taiwan University found that patients who improved after antidepressant treatment maintained a more balanced and functional microbial ecosystem, recovered beneficial metabolites, and displayed blood-based biological signals that aligned with these changes. http://www.bioworld.com/articles/732354 Tue, 30 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732354-cinp-2026-gut-microbiota-could-predict-antidepressant-response Illustration demonstrating gut-brain axis While the U.S. Supreme Court made it clear earlier this month in Hikma v. Amarin that skinny labels are still on the board for generics, the court didn’t resolve all disagreements over the generic carveouts. Hikma v. Amarin that skinny labels are still on the board for generics, the court didn’t resolve all disagreements over the generic carveouts.]]> http://www.bioworld.com/articles/732229 Mon, 29 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/732229-the-court-said-what-it-said-dc-circuit-tells-norwich Judge's gavel with US flag The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of antidepressant-naive patients presented at the 2026 World Congress of Neuropsychopharmacology (CINP), scientists from National Taiwan University found that patients who improved after antidepressant treatment maintained a more balanced and functional microbial ecosystem, recovered beneficial metabolites, and displayed blood-based biological signals that aligned with these changes. http://www.bioworld.com/articles/732204 Mon, 29 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732204-cinp-2026-gut-microbiota-could-predict-antidepressant-response Illustration demonstrating gut-brain axis Pharmgen Science Inc. has patented H+/K+-ATPase inhibitors that are potentially useful for the treatment of asthma, esophagitis, Helicobacter pylori infection, gastroesophageal reflux disease, gastritis, peptic ulcer and more. Helicobacter pylori infection, gastroesophageal reflux disease, gastritis, peptic ulcer and more.]]> http://www.bioworld.com/articles/732197 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732197-pharmgen-science-characterizes-new-h-k-atpase-inhibitors Receptor-interacting protein kinase 1 (RIPK1) acts as a central signaling node regulating apoptosis, necroptosis and inflammatory pathways. Researchers from China Pharmaceutical University reported the discovery and preclinical characterization of LT-1339-553, a novel RIPK1 inhibitor, in models of schistosomiasis-induced hepatic fibrosis. http://www.bioworld.com/articles/732192 Fri, 26 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732192-new-ripk1-inhibitor-protects-from-hepatic-fibrosis 3D molecular model illustration of RIPK1 RIPK1 Spyre Therapeutics Inc.’s striking “two for two” data on ulcerative colitis (UC) candidates, SPY-001 and SPY-002, drew applause from multiple analysts, putting eyes on the Boston biotech’s upcoming top-line data of anti-IL-23 antibody SPY-003 – the third biologic module in a six-strong inflammatory bowel disease (IBD) lineup. http://www.bioworld.com/articles/731905 Wed, 17 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731905-spyres-skyline-uc-double-win-lifts-hopes-for-ibd-antibody-combos Gastrointestinal system Zealand Pharma A/S has identified new interleukin-23 receptor (IL-23R) antagonists potentially useful for the treatment of Crohn’s disease, ulcerative colitis, psoriasis and psoriatic arthritis. http://www.bioworld.com/articles/732002 Wed, 17 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/732002-zealand-pharma-reports-il-23r-antagonists Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on the GLP-1 receptor but instead on the gut microbiota, since the treatment increases the presence of the bacterium Lactobacillus delbrueckii. Lactobacillus delbrueckii. ]]> http://www.bioworld.com/articles/731977 Mon, 15 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731977-microbiota-modulates-the-antidepressant-effects-of-glp-1-analogues Illustration of Lactobacillus Lactobacillus Researchers from Medizinische Hochschule Hannover and collaborators thus aimed to elucidate signaling adaptations following MAPK pathway inhibition in BRAFV 600E mutant cholangiocarcinoma (CCA) by generating a BRAF V600E-driven model of CCA. http://www.bioworld.com/articles/731859 Fri, 12 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731859-development-of-a-braf-v600e-cholangiocarcinoma-model-in-mice Illustration of cancer in the bile ducts Liraglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist used in diabetes and obesity, could alleviate depression through a pathway that does not depend on the GLP-1 receptor but instead on the gut microbiota, since the treatment increases the presence of the bacterium Lactobacillus delbrueckii. This symbiotic microorganism produces a lipid that modulates neuronal activity, normalizing the hyperactivation of brain regions in mice involved in emotional processing, which ultimately reduces depressive behaviors. Lactobacillus delbrueckii. This symbiotic microorganism produces a lipid that modulates neuronal activity, normalizing the hyperactivation of brain regions in mice involved in emotional processing, which ultimately reduces depressive behaviors.]]> http://www.bioworld.com/articles/731833 Thu, 11 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731833-microbiota-modulates-the-antidepressant-effects-of-glp-1-analogues Illustration of Lactobacillus Lactobacillus Researchers from Beijing University of Chinese Medicine described the role of TRIM54 in cirrhosis progression using two independent animal models of chronic liver injury – a DEN-induced rat model and a CCl4-induced mouse model of liver cirrhosis. http://www.bioworld.com/articles/731782 Wed, 10 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731782-targeting-trim54-mitigates-liver-injury-in-cirrhosis Liver anatomy on medical background Extracellular matrix specialist Engitix Ltd. is teaming up with GSK plc to delve into the mechanisms underlying regression of fibrosis after treatment for chronic liver disease, and identify and validate new drug targets involved in this process. http://www.bioworld.com/articles/731798 Tue, 09 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731798-engitix-seals-gsk-deal-for-targets-to-reverse-liver-fibrosis Liver Researchers from Rectify Pharmaceuticals Inc. presented preclinical efficacy data on RTY-406, a novel dual-acting ABCB4/MDR3 and ABCB11/BSEP modulator, in animal models of primary sclerosing cholangitis. http://www.bioworld.com/articles/731744 Mon, 08 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731744-dual-abcb4-abcb11-modulation-shows-promise-in-cholestatic-disease-models Liver anatomy illustration Genome-wide association studies (GWAS) have identified multiple loci associated with complex diseases, but these are mostly on regulatory genes in the non-coding part of the genome and it has proved difficult to identify the effector genes that they control. Now, researchers in the U.K. have shown how single cell sequencing at scale can be used to precisely link non-coding GWAS loci to specific protein coding genes and cell types. http://www.bioworld.com/articles/731755 Fri, 05 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731755-technique-links-non-coding-mutations-to-disease-genes-they-regulate Gastrointestinal system with DNA, scientific background The microbiome and a frontline innate antimicrobial sensor, Toll-like receptor 5 (TLR5), play an essential role in the development of idiopathic pulmonary fibrosis (IPF). A scientific collaboration led by researchers at the National Institute of Environmental Health Sciences has revealed how TLR5 protects against fibrosis through its ability to modulate the lung microbiome. Their study also shows that activating TLR5 protects against fibrosis and corrects pulmonary dysbiosis. http://www.bioworld.com/articles/731651 Thu, 04 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731651-innate-immunity-and-microbiome-allied-against-pulmonary-fibrosis Illustration of therapies for lung diseases Genome-wide association studies (GWAS) have identified multiple loci associated with complex diseases, but these are mostly on regulatory genes in the non-coding part of the genome and it has proved difficult to identify the effector genes that they control. Now, researchers in the U.K. have shown how single cell sequencing at scale can be used to precisely link non-coding GWAS loci to specific protein coding genes and cell types. http://www.bioworld.com/articles/731544 Wed, 03 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731544-technique-links-non-coding-mutations-to-disease-genes-they-regulate Gastrointestinal system with DNA, scientific background Shiga toxin-producing Escherichia coli (STEC) represents a public health threat that can lead to serious problems, such as bloody diarrhea and hemolytic uremic syndrome in children in up to 10%-15% of cases. Antibiotics that normally combat diarrhea are not recommended for STEC infections and patients are usually treated only for symptomatology. Now, French researchers from Eligo Bioscience SA and their collaborators have published a paper on a CRISPR-based antimicrobial approach, EB-003. Escherichia coli (STEC) represents a public health threat that can lead to serious problems, such as bloody diarrhea and hemolytic uremic syndrome in children in up to 10%-15% of cases. Antibiotics that normally combat diarrhea are not recommended for STEC infections and patients are usually treated only for symptomatology. Now, French researchers from Eligo Bioscience SA and their collaborators have published a paper on a CRISPR-based antimicrobial approach, EB-003.]]> http://www.bioworld.com/articles/731670 Wed, 03 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731670-crispr-based-approach-fights-pathogenic-eme-coli-em Illustration of E. coli with window showing DNA E.coli. Credit: Thom Leach. License: CC by SA Transforming growth factor-β-activated kinase 1 (TAK1) is a crucial central signaling molecule of hepatic cell death, inflammation and fibrogenesis through NF-κB and MAPK in metabolic dysfunction-associated steatotic liver disease (MASLD). Its pharmacological inhibition using the TAK1 inhibitor HS-276 was tested in vivo in a murine model of diet-induced MASLD. http://www.bioworld.com/articles/731600 Wed, 03 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731600-tak1-emerges-as-a-therapeutic-target-in-masld Illustration of doctors examining a liver with magnifier and microscope There is a growing consensus that alcohol-related liver disease (ALD) should be considered a metabolic disorder under the influence of the gut-liver axis. Metabolome data have highlighted fatty acid-activated G protein-coupled receptors (GPCRs) as the main affected pathways, where the relationship of G-protein-coupled receptor 119 (GPR119) with ALD remains unexplored. http://www.bioworld.com/articles/731599 Wed, 03 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731599-gpr119-activation-ameliorates-alcohol-related-liver-disease Photomicrograph of liver biopsy in a patient with cirrhosis. Photomicrograph of liver biopsy in a patient with cirrhosis, showing bridging septal fibrosis and regenerative nodules. Stained with trichrome to highlight fibrosis (blue). Adipose triglyceride lipase (ATGL), a central mediator of triglyceride hydrolysis and fatty acid mobilization, modulates hepatic lipid homeostasis and metabolic signaling pathways that contribute to the activation of fibrogenic responses. http://www.bioworld.com/articles/731598 Wed, 03 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731598-atgl-inhibition-reshapes-immunometabolism-in-liver-fibrosis Doctor pointing at liver Researchers from Ospedale San Raffaele presented the preclinical characterization of SR-1891, a long-acting capsid assembly modulator (CAM) in models of chronic hepatitis B. In Hepa D38 cells, the compound exhibited EC50 and EC90 values of 0.2 and 0.8 nM, respectively, without any detectable cytotoxicity. http://www.bioworld.com/articles/731594 Wed, 03 Jun 2026 09:00:00 -0400 https://www.bioworld.com/articles/731594-sr-1891-achieves-prolonged-hbv-suppression-with-one-dose Hanmi Pharmaceutical Co. Ltd. secured a $1.26 billion deal with Eli Lilly and Co. to out-license ex-Korea rights to sonefpeglutide (HM-15912), a Lapscovery-based glucagon-like peptide-2 analog in development for multiple indications, including an ongoing phase II study of short bowel syndrome. It was one of two billion-dollar Asian company deals signed by Lilly on June 1, with the second transaction involving Haisco Pharmaceutical Group Co. Ltd., of Beijing. http://www.bioworld.com/articles/731645 Tue, 02 Jun 2026 12:00:00 -0400 https://www.bioworld.com/articles/731645-hanmi-haisco-win-billion-dollar-partnerships-with-eli-lilly Hanmi signage Credit: Hanmi Pharmaceutical Co. Ltd.